imiquimod has been researched along with mart-1 antigen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caron, D; Cebon, J; Chen, Q; Chen, W; Davis, ID; Dimopoulos, N; Hopkins, W; Jackson, H; Jefford, M; Maraskovsky, E; Masterman, KA; Parente, P; Shackleton, M; Tai, T | 1 |
| Bachmann, MF; Baumgaertner, P; Dummer, R; Geldhof, C; Goldinger, SM; Hammann-Haenni, A; Kündig, TM; Michielin, O; Mihic-Probst, D; Prior, JO; Schwarz, K; Speiser, DE; Willers, J | 1 |
| Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y | 1 |
2 trial(s) available for imiquimod and mart-1 antigen
| Article | Year |
|---|---|
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cytokines; Dendritic Cells; Female; Humans; Imiquimod; Immunotherapy, Active; Male; MART-1 Antigen; Melanoma; Membrane Proteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Peptide Fragments | 2004 |
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Topics: Adjuvants, Immunologic; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Flow Cytometry; Freund's Adjuvant; Humans; Imiquimod; Immunologic Memory; Ligands; Lipids; MART-1 Antigen; Melanoma; Nanoparticles; Oligodeoxyribonucleotides; Skin Neoplasms; Statistics, Nonparametric; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2012 |
1 other study(ies) available for imiquimod and mart-1 antigen
| Article | Year |
|---|---|
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7 | 2014 |